{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:17:02Z","timestamp":1740179822395,"version":"3.37.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>A 54-year-old woman developed stage IV breast cancer 8\u2009years prior. Chemotherapy was administered, and she was started on zoledronic acid treatment for her bone metastases. Her chemotherapy regimen was then switched, owing to disease progression. Fifty-seven months after starting treatment with zoledronic acid, the patient suffered an atypical femoral fracture of her right femur, for which she underwent surgery. Twenty months later, she developed another atypical femoral fracture in her left femur and underwent intramedullary nail fixation.<\/jats:p>\n               <jats:p>Zoledronic acid and denosumab use in patients with metastatic bone tumours caused by breast cancer should be done cautiously, considering atypical femoral fracture risk.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae059","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:05:59Z","timestamp":1727953559000},"page":"41-45","source":"Crossref","is-referenced-by-count":2,"title":["Bilateral atypical femur fracture in a patient with breast cancer taking zoledronic acid and denosumab: A case report"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-0063","authenticated-orcid":false,"given":"Kazuhiko","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"2025011615472730900_R1","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3390\/curroncol28050290","article-title":"Current overview of treatment for metastatic bone disease","volume":"28","author":"Tsukamoto","year":"2021","journal-title":"Curr Oncol"},{"key":"2025011615472730900_R2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jbmr.3618","article-title":"Understanding the bone in cancer metastasis","volume":"33","author":"Fornetti","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2025011615472730900_R3","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00590-022-03314-y","article-title":"Atypical femur fractures associated with bisphosphonate therapy: post-operative outcomes","volume":"33","author":"Murphy","year":"2023","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"2025011615472730900_R4","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.2106\/JBJS.L.00568","article-title":"Atypical femoral fractures: what do we know about them? AAOS Exhibit Selection","volume":"95","author":"Unnanuntana","year":"2013","journal-title":"J Bone Joint Surg Am"},{"key":"2025011615472730900_R5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"2025011615472730900_R6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beem.2017.04.010","article-title":"Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer","volume":"31","author":"Verburg","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2025011615472730900_R7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"2025011615472730900_R8","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025011615472730900_R9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025011615472730900_R10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2025011615472730900_R11","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1002\/cncr.33035","article-title":"Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab","volume":"126","author":"Suarez-Almazor","year":"2020","journal-title":"Cancer"},{"key":"2025011615472730900_R12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115901","article-title":"Adverse events associated with bone-directed therapies in patients with cancer","volume":"158","author":"Jara","year":"2022","journal-title":"Bone"},{"key":"2025011615472730900_R13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.798653","article-title":"Case report: prophylactic plate fixation for incomplete atypical ulnar fractures resulting from the use of denosumab for bone metastases","volume":"12","author":"Murai","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025011615472730900_R14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2025011615472730900_R15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jbmr.3657","article-title":"Diagnosis and management of Paget\u2019s disease of bone in adults: a clinical guideline","volume":"34","author":"Ralston","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025011615472730900_R16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"2025011615472730900_R17","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-021-00944-3","article-title":"Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center","volume":"16","author":"Bareli","year":"2021","journal-title":"Arch Osteoporos"},{"key":"2025011615472730900_R18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00774-012-0358-0","article-title":"Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series","volume":"30","author":"Sasaki","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"2025011615472730900_R19","first-page":"567","article-title":"Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates): a systemic review of literature","volume":"76","author":"Agarwal","year":"2010","journal-title":"Acta Orthop Belg"},{"key":"2025011615472730900_R20","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.2106\/JBJS.H.01774","article-title":"Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy","volume":"91","author":"Capeci","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"2025011615472730900_R21","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N Engl J Med"},{"key":"2025011615472730900_R22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy","volume":"22","author":"Yang","year":"2017","journal-title":"Oncologist"},{"key":"2025011615472730900_R23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12282-016-0746-8","article-title":"Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis","volume":"24","author":"Ota","year":"2017","journal-title":"Breast Cancer"},{"key":"2025011615472730900_R24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/RLU.0000000000002058","article-title":"Impending atypical femoral fracture in a patient of breast cancer with bone metastases receiving long-term denosumab","volume":"43","author":"Sugihara","year":"2018","journal-title":"Clin Nucl Med"},{"key":"2025011615472730900_R25","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-022-01166-x","article-title":"Atypical femoral fracture in a bisphosphonate-na\u00efve patient on denosumab for osteoporosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Arch Osteoporos"},{"key":"2025011615472730900_R26","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.CC.19.00545","article-title":"Unique form of atypical subtrochanteric femoral fracture at the medial cortex: a report of 3 cases","volume":"10","author":"Roh","year":"2020","journal-title":"JBJS Case Connect"},{"key":"2025011615472730900_R27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2106\/JBJS.23.00583","article-title":"Atypical versus typical subtrochanteric femoral fractures: disparate patient profiles, similar outcomes","volume":"106","author":"Gibbons","year":"2024","journal-title":"J Bone Joint Surg Am"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae059\/59762982\/rxae059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/41\/59762982\/rxae059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/41\/59762982\/rxae059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T15:54:14Z","timestamp":1737042854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/9\/1\/41\/7808530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,3]]},"published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae059","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,3]]}}}